Hepatitis C: State of Medicaid Access Report Card

Michigan



Grade	Recommendations to Improve Patient Access
A+	• Continue to ensure broad access to HCV treatment

State Overview

As of July 2026, 2,120,547 individuals were enrolled in Medicaid and CHIP in Michigan.[1] While Michigan Medicaid contracts with managed care organizations (MCOs), HCV medications are carved out of MCO contracts and administered by the state,[2] as Michigan Medicaid purchases Mavyret via a modified subscription model contract that began April 1, 2021.[3] In a federal analysis of 2023-2024 Medicaid claims data, only 28% of Michigan adult Medicaid beneficiaries newly identified with HCV received timely HCV treatment.[4]

The Michigan Medicaid Preferred Drug List designates Mavyret as the preferred HCV treatment regimen, pursuant to the modified subscription model contract[5] The Michigan Department of Health & Human Services has a publicly available data dashboard on HCV treatment for Medicaid beneficiaries.[6]

Deductions		Policy
Prior Authorization		Prior authorization is not required for the preferred regimen (Mavyret).[7]
Fibrosis Restrictions		Michigan Medicaid does not impose fibrosis restrictions.[8]
Substance Use Restrictions		Michigan Medicaid does not impose substance use restrictions.[9]
Prescriber Restrictions		Michigan Medicaid does not impose prescriber restrictions.[10]
Retreatment Restrictions		Michigan Medicaid does not impose retreatment restrictions.[11]
Access in Managed Care		As a result of the modified subscription model for Mavyret, HCV treatment is carved out of MCO contracts. [12]
Additional Restrictions		Michigan Medicaid does not impose additional restrictions.[13]

Total Deductions	Total Score [100-Deductions]	Grade
0	100	A+

Contact Your State Officials

Michigan Medicaid Office[14]: Meghan Groen, Medicaid Director, Department of Community Health
400 South Pine Street, Lansing, Michigan, 48913

Pharmacy & Therapeutics Committee[15]: Trish Bouck
Telephone: (517) 335-5442; Email address: bouckt@michigan.gov

Key Sources

Preferred Drug List: Michigan Medicaid Preferred Drug List (Oct. 26, 2026)
Clinical Criteria (for Non-Preferred Regimens): Michigan Medicaid Clinical and PDL Criteria (Nov. 1, 2026)

[1] Centers for Medicare & Medicaid Services, Medicaid & CHIP in Michigan, https://perma.cc/8WEB-MGYR.
[2] Michigan Department of Health and Human Services, Medicaid Health Plan Common Formulary (Nov. 1, 2024), https://perma.cc/C4AX-M3WD; MDHHS Health Plan Pharmacy Programs Carve-Out (Oct. 13, 2026), https://perma.cc/LT25-M8WC.
[3] Michigan Department of Health and Human Services, We Treat Hep C, https://perma.cc/XM7P-3NK2.
[4] U.S. Department of Health and Human Services, Office of Inspector General, Less Than 25 Percent of Medicaid Beneficiaries With Hepatitis C Received Treatment Within 6 Months, Data Brief OEI-BL-24-00450 (Nov. 2, 2026), https://perma.cc/PDA7-HQUM.
[5] Preferred Drug List.
[6] Michigan Department of Health & Human Services, We Treat Hep C, https://perma.cc/XM7P-3NK2.
[7] Preferred Drug List.
[8] Clinical Criteria.
[9] Clinical Criteria.
[10] Clinical Criteria.
[11] Clinical Criteria.
[12] Maryland Department of Health and Human Services, Health Plan Pharmacy Programs Carve-Out (Oct. 13, 2026). https://perma.cc/LT25-M8WC.
[13] Clinical Criteria.
[14] National Association of Medicaid Directors, Medicaid Directors, https://perma.cc/8XA7-39SZ.
[15] Michigan Department of Health and Human Services, Michigan Pharmacy and Therapeutics Committee, https://perma.cc/M88L-8F38.